MedPath

Effect of moderate wine consumption on the clinical symptoms of patients with inflammatory bowel disease

Not Applicable
Completed
Conditions
lcerative colitis
Digestive System
Ulcerative colitis
Registration Number
ISRCTN11169656
Lead Sponsor
Institute of Food Science Research
Brief Summary

2022 Results article in https://doi.org/10.1002/mnfr.202101073 (added 14/06/2022)

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
10
Inclusion Criteria

Patients diagnosed with mild or moderate ulcerative colitis

Exclusion Criteria

1. Antibiotic intake up to 6 months before the study
3. Type I diabetes, endocrine and gastrointestinal disorders
4. Addiction to drugs or alcohol
5. Restrictive diets (vegetarians, vegans)

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Markers of ulcerative colitis such as fecal calprotectin, iron, ferritin, C-reactive protein and white and blood cells measured by routine blood tests at initial and end treatment point (4 weeks)
Secondary Outcome Measures
NameTimeMethod
<br> 1. Quality of life measured by quality of life questionnaires (IBDQ-32) at initial and end treatment point (4 weeks)<br> 2. Microbial phenolic metabolites in faeces and urine measured by ultra-high-performance liquid chromatography–electrospray ionization–?tandem mass spectrometry (UHPLC-ESI-MS/MS) at initial and end treatment point (4 weeks)<br> 3. Short and medium-chain fatty acids in faeces measured by solid-phase microextraction gas chromatography-mass spectrometry (SPME-GC-MS) at initial and end treatment point (4 weeks)<br> 4. Composition, abundance and diversity of the faecal microbiota measured by sequencing the V3-V4 region of ribosomal DNA from fecal samples and metagenomic analysis at initial and end treatment point (4 weeks)<br>
© Copyright 2025. All Rights Reserved by MedPath